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To develop a statistical model to identify determinants of glycemic control.
Materials and methods
A database was extracted from patients’ records with at least one glycated hemoglobin
(HbA1c) analysis and with antidiabetic therapy established and stabilized. A logistic regres-
sion model was designed to identify the statistical significance of factors associated with gly-
cemic control.
Results
Higher probability of success (HbA1c�8% [64 mmol/mol]) was found for those who were
older in age, those who were men, and those with higher education levels. Increased values
for the following variables were associated with the poorest glycemic control: number of
years of T2DM since diagnosis, number of antidiabetic medicines, body mass index, low-
density lipoprotein cholesterol, triglycerides, systolic blood pressure and number of diabetes
consultations in the last twelve months. The following pharmacotherapeutic treatments
were associated with glycemic control (in decreasing order of the results): oral antidiabetic
drugs; oral antidiabetic drugs and insulin; insulin. Patients using metformin and a dipeptidyl
peptidase-4 inhibitors have a higher probability of success than do patients using metformin
and a sulfonylurea, and patients using insulin and metformin have a higher probability of
success than do patients using insulin alone.
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Conclusions
Sociodemographic, clinical and therapeutic parameters can strongly affect glycemic control.
Studies based on real-life patient data provide important information on the development of
more effective glycemic control.
Introduction
Type 2 diabetes mellitus (T2DM) is a chronic disease whose onset can be a years-long process;
moreover, T2DM can lead to multiple diabetes-related complications [1–3]. It is believed that
good glycemic control is the best way to prevent diabetes complications [4]. However, 40–60%
of individuals with T2DM are considered to have suboptimal glycemic control [5].
Patients with poor glycemic control who have multiple diabetes complications or who have
had T2DM for many years are sometimes referred to specialized diabetes clinics, thus facilitat-
ing a multifactorial approach to this complex disease [6] and usually obtaining better health
results [7]. A wide range of antidiabetic medicines is available [8], and several therapeutic
schemes can be prescribed to patients, including treatment with one or more noninsulin
drugs, insulin in monotherapy or a combination of these two types of medicines [9].
In some cases, after a patient’s clinical and nonclinical characteristics are analyzed, glycemic
control may be considered to be acceptable even with a glycated hemoglobin (HbA1c) value
above that generally recommended [10]. To achieve successful glycemic control, it is impor-
tant to be aware of the related determinants [11].
The aim of this study was the creation of a statistical model based on logistic regression pre-
dicting the outcome of glycemic control from determinant variables, allowing for the adjust-
ment of confounding effects in individuals with T2DM with stabilized antidiabetic
pharmacotherapeutic treatment (oral antidiabetic drugs [OAD]; OAD and insulin; insulin).
Other objectives of this study were the model re-estimations of the following treatments: i)
metformin and a sulfonylurea versus metformin and a dipeptidyl peptidase-4 (DPP-4) inhibi-
tor; and ii) insulin versus insulin and metformin.
Materials and methods
The database was extracted from informatics records of a specialized clinic in diabetes (Portu-
guese Diabetes Association [APDP]). The database included the information of all patients
who had at least one HbA1c laboratory analysis in 2012 (if patients had more than one analy-
sis, the last one was used in the study) and who satisfied all the following criteria: i) at least one
year of follow-up diabetes consultation; ii) at least one diabetes consultation in the last twelve
months; and iii) antidiabetic therapy established and stabilized for at least 181 days.
The logistic regression model was designed with the objective of identifying statistically sig-
nificant factors associated with glycemic control (HbA1c�8.0% [64 mmol/mol]). Age and sex
were included in the model because they can be potential confounders. The education level
variable was also included as a proxy for economic, social and health-related characteristics.
This variable has some missing data (1694; 32.6%). However, it was included in the model
because of its impact on the outcome. After these variables, other variables of the following
groups were successively tested: i) diabetes characterization (age at time of T2DM diagnosis;
years of T2DM since diagnosis); ii) antidiabetic pharmacological therapy (duration of current
therapy; pharmacotherapeutic treatment [OAD; OAD and insulin; insulin]; number of differ-
ent antidiabetic medicines); iii) laboratory parameters of renal function (glomerular filtration
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rate; albuminuria); iv) anthropometric, metabolic and behavioral characteristics (body mass
index [BMI]; abdominal perimeter; total cholesterol; high-density lipoprotein [HDL] choles-
terol; low-density lipoprotein [LDL] cholesterol; non-HDL cholesterol; triglycerides; both sys-
tolic and diastolic blood pressure [SBP and DBP]; smoking); and v) access to health care
(medication reimbursement system; number of diabetes consultations in the last twelve
months). In each group of variables, multicollinearity was evaluated to prevent the high corre-
lation of variables in the model.
In the process of variable selection, the following aspects were considered: i) lower p-value
associated with the significance of the parameter to the variable; ii) greater reduction in the
value of the statistical Akaike information criterion; and iii) absence of collinearity problems
with variables included in the previous stage model.
For statistical calculations, the software R (version 3.2.0) was used.
This study obtained approval from the Ethical Committee of APDP (number 273/2013;
from 8th of April). The database was received in an anonymized information format.
Results
Statistical modeling of glycemic control (HbA1c�8.0% [64 mmol/mol]);
antidiabetic pharmacotherapeutic treatment: OAD versus OAD and
insulin versus insulin
As described in the Materials and Methods section, several variables were tested during the
development of the logistic regression model of glycemic control (HbA1c�8.0% [64 mmol/
mol]). Table 1 includes only variables that were statistically significant as variables non-statisti-
cally significant did not contribute to the statistical model.
For model estimation, 3454 cases with complete information for the study variables were
included. For more patient’s details, please see Table 2 (column A).
Being older in age and being a man were significantly associated with better outcomes
(Table 1). Additionally, having a higher level of education is progressively more associated
with better outcomes. In contrast, a lower probability of success was associated with a longer
length of time with T2DM, taking more antidiabetic medicines, and having higher values of
BMI, LDL-cholesterol, triglycerides and SBP. More diabetes consultations are also associated
with a lower probability of success. Patients taking OAD associated with insulin or taking insu-
lin only have a significantly lower probability of success than do patients taking OAD.
Model robustness
Only 44 cases (1.3%) were observed to be out of range for standardized Pearson residuals
[-2;2]. Regarding the standardized deviance residuals, 7 cases (0.2%) were observed to be out
of range. In relation to the diagonal values of matrix H (hat-values) and Cook distance values,
only one case had high levels for both measures. This case also had a high standardized Pear-
son residual. This specific case had the following characteristics: adequate glycemic control
(HbA1c�8.0% [64 mmol/mol]); 61 years old; man; high school education level; 17 years of
T2DM since the diagnosis; OAD associated with insulin treatment; 3 antidiabetic medicines;
BMI of 36.5 kg/m2; LDL-cholesterol of 117 mg/dl; triglyceride level of 1473.5 mg/dl; SBP of
145 mmHg; and 2 diabetes consultations in the last twelve months. The exclusion of this case
and the re-estimation of the model did not change the meaning of the variable’s coefficients
(Table 3). In this re-estimation, no cases showed high hat-values and high Cook’s distance val-
ues simultaneously. Also, with respect to standardized Pearson residuals, there were no cases
that were out of range.
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To test the quality of the model adjustment, the Hosmer-Lemeshow test was performed. A
total of G = 10 groups were considered, and a value of H = 8.071335 (p-value = 0.4265) was
obtained; hence, evidence of a lack of fit was found. According to the McFadden proposal, the
pseudo-R2 (0.3909) was calculated.
With this model, the area under the curve (AUC = 0.6942) for the receiver operating char-
acteristic (ROC) curve was calculated. This value is in the higher borderline range of reason-
able, which is very close to the range of good.
Metformin and a sulfonylurea versus metformin and a DPP-4 inhibitor
(HbA1c�8.0% [64 mmol/mol])
For comparison of different therapeutic treatments, the same model was applied by changing
the pharmacotherapeutic treatment variable to the category metformin combined with a sulfo-
nylurea and the category metformin combined with a DPP-4 inhibitor. In this model estima-
tion, 284 cases were included. For more patient’s details, please see Table 2 (column B).
The dummy variable for the category metformin and a DPP-4 inhibitor presents a positive
value for the coefficient estimate and a p-value <0.01 (Table 4). These results indicate that,
maintaining the conditions for the other variables, patients with metformin and a DPP-4
inhibitor treatment have a higher probability of success (HbA1c�8.0% [64 mmol/mol]), with
Table 1. Summary of the statistical model for glycemic control: HbA1c�8.0% (64 mmol/mol); antidiabetic pharmacotherapeutic treatment: OAD versus OAD and
insulin versus insulin.
Variable Estimate Standard error z †p-Value ‡OR ‡CI 95%; ‡OR
(Intercept) 2.147 0.515 4.168 <0.0001���
Age (years) 0.019 0.004 4.409 <0.0001��� 1.019 1.011–1.027
Sex:
Woman (reference category)
Man 0.240 0.077 3.121 0.0018�� 1.271 1.093–1.478
Educational level:
No education (reference category)
Primary school 0.603 0.179 3.368 0.0008��� 1.828 1.287–2.596
High school 0.726 0.193 3.761 0.0002��� 2.067 1.416–3.017
Higher education 0.756 0.221 3.418 0.0006��� 2.129 1.381–3.284
Years of T2DM since diagnostic -0.010 0.004 -2.234 0.0255� 0.990 0.982–0.998
Pharmacotherapeutic treatment:
OAD (reference category)
OAD + Insulin -0.807 0.096 -8.446 <0.0001��� 0.446 0.370–0.539
Insulin -1.235 0.114 -10.790 <0.0001��� 0.291 0.233–0.364
Number of antidiabetic medicines -0.223 0.042 -5.371 <0.0001��� 0.800 0.737–0.869
BMI (kg/m2) -0.021 0.008 -2.625 0.0087�� 0.979 0.964–0.995
LDL-cholesterol (mg/dl) -0.005 0.001 -4.643 <0.0001��� 0.995 0.993–0.997
Triglycerides (mg/dl) -0.002 <0.001 -3.955 0.0001��� 0.998 0.998–0.998
SBP (mmHg) -0.005 0.002 -2.703 0.0069�� 0.995 0.991–0.999
Number of diabetes consultations in the last 12 months -0.251 0.046 -5.477 <0.0001��� 0.778 0.711–0.851
†Significance: • p-value- <0.10
�p-value <0.05
�� p-value <0.01
��� p-value <0.001 /
‡ Odds ratio (OR) and Confidence interval (CI).
https://doi.org/10.1371/journal.pone.0235376.t001
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Table 2. Patients’ main characteristics for model estimation with different pharmacotherapeutic profiles.
A B C
Patients (N) 3454 284 1665
Age; average (years) 66.0 65.1 67.5
Sex
Women (%) 49.0 42.3 53.6
Time since diagnosis of T2DM; average (years) 18.6 13.3 23.1
Pharmacotherapeutic treatment
A OAD (n) 967
OAD + Insulin (n) 1663
Insulin (n) 824
B Metformin + Sulphonylurea (n) 162
Metformin + DPP-4 inhibitor (n) 122
C Insulin (n) 824
Insulin + Metformin (n) 841
Glycaemic control
Glycaemic controlled (n) 1777 213 759
Not glycaemic controlled (n) 1677 71 906
A (OAD / OAD + Insulin / Insulin); B (Metformin + Sulphonylurea / Metformin + DPP-4 inhibitor); C (Insulin /
Insulin + Metformin).
https://doi.org/10.1371/journal.pone.0235376.t002
Table 3. Estimate and odds ratio for recalculation of the statistical model for glycemic control (HbA1c�8.0% [64
mmol/mol]) after the exclusion of one specific case.
Variable Estimate ‡OR
(Intercept) 2.149





No education (reference category)
Primary school 0.605 1.830
High school 0.727 2.068
Higher education 0.740 2.095
Years of T2DM since diagnostic -0.010 0.990
Pharmacotherapeutic treatment:
OAD (reference category)
OAD + Insulin -0.810 0.445
Insulin -1.238 0.290
Number of antidiabetic medicines -0.223 0.800
BMI (kg/m2) -0.021 0.980
LDL-cholesterol (mg/dl) -0.005 0.995
Triglycerides (mg/dl) -0.002 0.998
SBP (mmHg) -0.005 0.995
Number of diabetes consultations in the last 12 months -0.250 0.779
‡ Odds ratio (OR).
https://doi.org/10.1371/journal.pone.0235376.t003
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an increase of 175.3% [CI 95% 1.325;5.721], than patients with metformin and a sulfonylurea
treatment. Both high school and higher education levels also have positive coefficient estimates
and are statistically significant.
Insulin versus insulin and metformin (HbA1c�8.0% [64 mmol/mol])
For the comparison of insulin therapy versus insulin and metformin therapy, the same model
was applied by changing the respective categories of pharmacotherapeutic treatment variables.
In this model estimation, 1665 cases were included. For more patient’s details, please see
Table 2 (column C).
The dummy variable for the category insulin and metformin treatment presents a positive
value for the coefficient estimate and a p-value <0.01 (Table 5). These findings indicate that,
maintaining the conditions for the other variables, patients with insulin and metformin treat-
ment have a higher probability of success (HbA1c�8.0% [64 mmol/mol]), with an increase of
71.8% [CI 95% 1.329;2.220], than the patients with insulin monotherapy treatment. Age and
sex (men) have positive coefficient estimates and are statistically significant. The number of
antidiabetic medicines, BMI, LDL-cholesterol, triglycerides and the number of diabetes con-
sultations in the last twelve months have negative coefficient estimates and are statistically
significant.
Table 4. Summary of the statistical model for glycemic control (HbA1c�8.0% [64 mmol/mol]) in patients on metformin and a sulfonylurea treatment versus in
patients on metformin and a DPP-4 inhibitor treatment.
Variable Estimate Standard error z †p-Value ‡OR ‡CI 95%; ‡OR
(Intercept) -1.384 2.377 -0.582 0.560
Age (years) 0.028 0.018 1.529 0.126 1.028 0.992–1.066
Sex:
Woman (reference category)
Man 0.563 0.316 1.780 0.075• 1.756 0.945–3.266
Educational level:
No education (reference category)
Primary school 1.536 0.800 1.921 0.055• 4.648 0.969–22.289
High school 2.229 0.858 2.597 0.009�� 9.292 1.728–49.973
Higher education 2.062 0.913 2.259 0.024� 7.865 1.314–47.078
Years of T2DM since diagnostic -0.001 0.020 -0.070 0.944 0.999 0.960–1.039
Number of antidiabetic medicines -0.293 0.333 -0.880 0.379 0.746 0.388–1.434
BMI (kg/m2) -0.007 0.033 -0.217 0.828 0.993 0.931–1.059
LDL-cholesterol (mg/dl) -0.003 0.005 -0.572 0.567 0.997 0.988–1.007
Triglycerides (mg/dl) 0.000 0.002 -0.212 0.832 1.000 0.996–1.003
SBP (mmHg) -0.006 0.007 -0.780 0.435 0.994 0.980–1.009
Number of diabetes consultations in the last 12 months 0.196 0.242 0.810 0.418 1.216 0.757–1.953
Pharmacotherapeutic treatment:
Metformin + Sulfonylurea (reference category)





��� p-value <0.001 /
‡ Odds ratio (OR) and Confidence interval (CI).
https://doi.org/10.1371/journal.pone.0235376.t004
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Discussion
There are several studies already published related with determinants of glycemic control but
there are different values to consider that glycemic control is achieved. Concerning the present
study, it is adequate to start the discussion with results from studies that chose approximately
the same target value.
In a nationwide study in the United States of America, with the outcome of success defined
as HbA1c <8.0% (64 mmol/mol), a logistic regression established statistical significance for
the variables age (older), sex (men) and therapeutic profile; furthermore, the probability of
success for therapeutic profile was as follows (in ascending order): OAD conjugated with insu-
lin; only insulin; only OAD [12]. Another nationwide epidemiologic study in Brazil, which
also defined the outcome of success as HbA1c<8.0% (64 mmol/mol), found a higher probabil-
ity of success in older people, patients who had T2DM for a shorter period of time and patients
who were not under insulin treatment; these findings were statistically significant [13]. In gen-
eral, these studies are in line with the determinants found on the present study; there is a
higher probability of glycemic control for men, older patients, and patients with less years of
T2DM since diagnosis. A common finding is that patients taking insulin have a lower proba-
bility of achieving glycemic control. Usually patients are first treated with OAD being insulin
Table 5. Summary of the statistical model for glycemic control (HbA1c�8.0% [64 mmol/mol]) in patients on insulin treatment versus in patients on insulin and
metformin treatment.
Variable Estimate Standard error z †p-Value ‡OR ‡CI 95%; ‡OR
(Intercept) 0.741 1.909 0.056•
Age (years) 0.018 0.006 2.930 0.003�� 1.018 1.006–1.031
Sex:
Woman (reference category)
Man 0.310 0.109 2.839 0.005�� 1.364 1.101–1.689
Educational level:
No education (reference category)
Primary school 0.275 0.236 1.161 0.246 1.316 0.828–2.092
High school 0.396 0.260 1.521 0.128 1.486 0.892–2.475
Higher education 0.485 0.329 1.474 0.141 1.624 0.852–3.095
Years of T2DM since diagnostic -0.007 0.006 -1.116 0.264 0.993 0.982–1.005
Number of antidiabetic medicines -0.321 0.085 -3.785 <0.001��� 0.725 0.614–0.856
BMI (kg/m2) -0.024 0.011 -2.129 0.033� 0.976 0.955–0.998
LDL-cholesterol (mg/dl) -0.005 0.002 -3.273 0.001�� 0.995 0.991–0.998
Triglycerides (mg/dl) -0.001 <0.001 -2.270 0.023� 0.999 0.998–1.000
SBP (mmHg) -0.005 0.003 -1.794 0.073• 0.995 0.991–1.000
Number of diabetes consultations in the last 12 months -0.335 0.066 -5.070 <0.001��� 0.715 0.629–0.814
Pharmacotherapeutic treatment:
Insulin (reference category)





��� p-value <0.001 /
‡ Odds ratio (OR) and Confidence interval (CI).
https://doi.org/10.1371/journal.pone.0235376.t005
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added to treatment at a later stage when the glycemic control fails. Thus, it is reasonable that
insulin is associated with the poorest results for glycemic control.
Other findings of the present study are that an increased number of antidiabetic medicines
prescribed and an increased number of diabetes consultations are associated with a worst gly-
cemic control, what probably reflects the fact that patients with poor glycemic control need
more drugs or tighter clinical follow-up.
Despite other studies selected lower glycemic control values, those studies are important to
have an overview of their findings. One study in primary care units in the United Kingdom
used logistic regression to examine glycemic control, defined as HbA1c�7.5% (59 mmol/
mol), and revealed a higher probability of success in older people and in patients treated with
five or fewer medicines (not only antidiabetic medicines); these findings were statistically sig-
nificant [14]. For glycemic control defined as HbA1c�7.0% (53 mmol/mol), another study in
Brazil performed in ambulatory patients from an university clinic detected a higher probability
of success in older people, patients with�100 mg/dl of LDL-cholesterol and patients without
insulin treatment; these findings were statistically significant [15]. For the same glycemic con-
trol level, a study performed in an endocrinology clinic in Beirut, Lebanon, showed a higher
probability of success in patients with <150 mg/dl of triglycerides and without insulin treat-
ment; these findings were statistically significant [16]. A study of glycemic control, defined as
HbA1c <7.0% (53 mmol/mol), that was performed in nationwide Chinese hospitals found a
higher probability of success in older people, women and those only under OAD treatment
(instead of OAD combined with insulin treatment); these findings were statistically significant
[17]. In individuals from the Jordan National Center for Diabetes, there was a higher probabil-
ity of success in patients who had T2DM for seven or fewer years; with respect to the therapeu-
tic profile, the ascending probability of success was as follows: both OAD and insulin; only
insulin; only OAD [18].
In these studies, the statistically significant variables are in line with the present study,
except for the study performed in Chinese in hospitals where women got more probability of
glycemic control. In the present study many metabolic variables where statistically significant
(BMI, LDL-cholesterol, triglycerides and SBP) and only two studies [15, 16] obtained statistical
significance for this type of variables.
However, not only clinical parameters are important to glycemic control. One of the most
important finding in the present study was that educational level has a strong association to a
successful glycemic control. This variable was not analysed or relevant in the studies previously
mentioned.
Concerning the specific treatments of metformin combined with a sulfonylurea versus met-
formin combined with a DPP-4 inhibitor, one German multicenter study followed individuals
with these treatments for twelve months. For the first treatment, at the beginning of the study,
patients had T2DM for an average of 5.4 years and had an average HbA1c value of 7.6±0.8%
(60±9 mmol/mol); at the end of the study, an average change of -0.6±0.9% (-7±10 mmol/mol)
was observed. For the second treatment, at the beginning of the study, patients had T2DM for
an average of 4.7 years and an average HbA1c value of 7.5±0.7% (59±8 mmol/mol); at the of
the study, an average change of -0.6±0.8% (-7±9 mmol/mol) was observed. No statistical sig-
nificance was observed between these two average changes in HbA1c [19].
In one study that focused on the addition of a sulfonylurea or a DPP-4 inhibitor to metfor-
min, the use of a DPP-4 inhibitor led to a higher proportion of patients with good glycemic
control (HbA1c <7% [53 mmol/mol]); these findings were statistically significant [20].
Another study also showed better results with a DPP-4 inhibitor than with a sulfonylurea, both
in addition to metformin, but these findings did not achieve statistical significance [21]. On
the present study, concerning the addition of a DDP-4 inhibitor versus a sulfonylurea to
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metformin, the result is very clear, as a strong statistical association was obtained: adding a
DDP-4 inhibitor leads to a better probability of glycemic control. However, we need to
consider that different populations, settings, and methodologies can lead to different out-
comes. Regardless the medicine added to metformin treatment, the introduction of a second
medicine, namely, a sulfonylurea or a DPP-4 inhibitor, leads to a decrease in HbA1c levels
[20–24].
One meta-analysis that included twenty studies on treatment with both insulin and metfor-
min versus treatment with only insulin presented an average reduction in HbA1c of 0.6% (7
mmol/mol) (CI 95% [-0.89, -0.31], p<0.001) in those treated with insulin combined with met-
formin [25]. The reduction in HbA1c levels with this type of drug combination continues to
be described in more recent studies [26, 27] and they are in line with the strong statistic associ-
ation revealed in the present study.
Regarding the limitations of this study, the information on this database is from 2012, and
we now have additional medicines. However, this advancement does not invalidate the statisti-
cal model and the comparison of different therapeutic treatments. The database was extracted
from clinic records and these records do not have information related with important aspects
such as income, rural or non-rural residence, marital status, and if the patient leaves alone or
not. Other important clinic information, such as other diseases or patient’s phenotypes could
not consistently be extracted from the records.
With respect to the setting (APDP), this clinic is established in Lisbon and it is well
known in Portugal. Many patients with diabetes are referred to this clinic, especially patients
without glycemic control, and all patients are follow-up by their own diabetologist doctor. The
statistical model was created for the outcome HbA1c�8.0% (64 mmol/mol) because in the
population under study, this glycemic level is a realistic goal with respect to patients’ profiles
[10].
In Portugal anyone living in the country has access to National Health Service (NHS). This
clinic has a protocol with the NHS, so it receives all kind of people, irrespectively of their origin
and level income. However, because of its location, most patients came from Lisbon Metropol-
itan Area. Therefore, this clinic is not representative of the Portuguese population with diabe-
tes, but it supports many patients with a difficult glycemic control.
Conclusions
In patients with T2DM, the determinants of the achievement of glycemic control are very
important. In this study, being older in age, being a man, and having a higher education level
were associated with better glycemic control. The increase in the value of the following vari-
ables was associated with the poorest glycemic control: number of years since T2DM diagno-
sis, number of antidiabetic medicines, BMI, LDL-cholesterol, triglycerides, SBP and number
of diabetes consultations in the last twelve months.
The pharmacotherapeutic treatment is associated with glycemic control. The patients
treated with OAD have more probability of glycemic control than patients treated with OAD
and insulin. The patients taking only insulin have the poorest probability of glycemic control.
When glycemic control is not established with metformin treatment, it is crucial to choose
a second medicine. The addition of a DPP-4 inhibitor or a sulfonylurea should be contem-
plated, with better results achieved with the former.
In patients with insulin treatment, maintaining metformin can be useful for better glycemic
control.
Finally, to develop better glycemic control, it is very important to understand the informa-
tion provided by studies based on real-life patient data.
PLOS ONE
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